Format

Send to

Choose Destination
Nat Commun. 2016 May 10;7:11463. doi: 10.1038/ncomms11463.

Generation of stem cell-derived β-cells from patients with type 1 diabetes.

Author information

1
Division of Endocrinology, Metabolism and Lipid Research, Washington University School of Medicine, Campus Box 8127, 660 South Euclid Avenue, St Louis, Missouri 63110, USA.
2
Department of Biomedical Engineering, Washington University in St Louis, 1 Brookings Drive, St Louis, Missouri 63130, USA.
3
Department of Stem Cell and Regenerative Biology, Harvard Stem Cell Institute, Harvard University 7 Divinity Avenue, Cambridge, Massachusetts 02138, USA.
4
Case Western Reserve University School of Medicine, 2109 Adelbert Road, Cleveland, Ohio 44106, USA.
5
Semma Therapeutics, Inc. 450 Kendall Street, Suite 2B Cambridge, Massachusetts 02142, USA.

Abstract

We recently reported the scalable in vitro production of functional stem cell-derived β-cells (SC-β cells). Here we extend this approach to generate the first SC-β cells from type 1 diabetic patients (T1D). β-cells are destroyed during T1D disease progression, making it difficult to extensively study them in the past. These T1D SC-β cells express β-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice and respond to anti-diabetic drugs. Furthermore, we use an in vitro disease model to demonstrate the cells respond to different forms of β-cell stress. Using these assays, we find no major differences in T1D SC-β cells compared with SC-β cells derived from non-diabetic patients. These results show that T1D SC-β cells could potentially be used for the treatment of diabetes, drug screening and the study of β-cell biology.

PMID:
27163171
PMCID:
PMC4866045
DOI:
10.1038/ncomms11463
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center